Page last updated: 2024-11-10

tresperimus

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID3086680
CHEMBL ID98034
SCHEMBL ID385624
MeSH IDM0243665

Synonyms (19)

Synonym
lf-08-0299
lf 08-0299
CHEMBL98034
tresperimus
[2-[6-(diaminomethylideneamino)hexylamino]-2-oxoethyl] n-[4-(3-aminopropylamino)butyl]carbamate
(4-((3-aminopropyl)amino)butyl)-2-((6-((aminoiminomethyl)amino)hexyl)amino)-2-oxoethyl carbamic acid ester
unii-286f595v8h
286f595v8h ,
160677-67-8
carbamic acid, (4-((3-aminopropyl)amino)butyl)-, 2-((6-((aminoiminomethyl)amino)hexyl)amino)-2-oxoethyl ester
tresperimus [inn:ban]
(4-((3-aminopropyl)amino)butyl)carbamic acid, ester with n-(6-guanidinohexyl)glycolamide
carbamic acid, n-(4-((3-aminopropyl)amino)butyl)-, 2-((6-((aminoiminomethyl)amino)hexyl)amino)-2-oxoethyl ester
tresperimus [inn]
SCHEMBL385624
DTXSID50166968
2-((6-guanidinohexyl)amino)-2-oxoethyl (4-((3-aminopropyl)amino)butyl)carbamate
Q27254273
AKOS040754242

Research Excerpts

Overview

Tresperimus is a novel agent that induces allogeneic transplant tolerance. It is under development by Laboratoires Fournier for its potential use in organ transplant rejection.

ExcerptReferenceRelevance
"Tresperimus (LF-08-0299) is an immunosuppressant under development by Laboratoires Fournier for its potential use in organ transplant rejection. "( Tresperimus (Laboratoires Fournier).
Elices, MJ, 2001
)
3.2
"Tresperimus is a novel agent that induces allogeneic transplant tolerance. "( Tresperimus: a new agent for transplant tolerance induction.
Simpson, D, 2001
)
3.2

Dosage Studied

ExcerptRelevanceReference
" A short term LF 08--0299 treatment at optimal dosage protected more than 75% of recipient mice from lethal GVHD induced either across minor antigens alone or the full H2 barrier."( Prevention of lethal graft-versus-host disease following allogeneic bone marrow transplantation in mice by short course administration of LF 08-0299.
Annat, J; Bruley-Rosset, M; Churaqui, E; Dutartre, P, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID186899Compound (6 mg/kg) is evaluated for prevention of graft rejection after heart allotransplantation in the Dark Agouti to Lewis rat combination.1999Journal of medicinal chemistry, Jan-28, Volume: 42, Issue:2
Structure-immunosuppressive activity relationships of new analogues of 15-deoxyspergualin. 1. Structural modifications of the hydroxyglycine moiety.
AID134268In vivo immunosuppressive activity in mouse GVHD (graft-versus-host disease) model and the mean survival days evaluated (dose of 3 mg/kg)1999Journal of medicinal chemistry, Jan-28, Volume: 42, Issue:2
Structure-immunosuppressive activity relationships of new analogues of 15-deoxyspergualin. 1. Structural modifications of the hydroxyglycine moiety.
AID1727031Immunosuppressive activity in B6D2F1 mouse model of graft-versus-host disease assessed as mean survival days at 3 mg/kg, ip administered for day 1 to day 10 (day 6 omitted) and measured at day 602020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.
AID134270Tested in vivo against mouse graft-versus-host disease(GVHD) for survival (mean) after daily administration of 0.3 mg/kg (i.p.) using group of 8 mice/dose for 10 days.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Structure-immunosuppressive activity relationships of new analogues of 15-deoxyspergualin. 2. Structural modifications of the spermidine moiety.
AID186900The compound was tested in vivo against heart transplanted rat for survival (mean) after daily administration of 2.5 mg/kg(ip) for 10 days.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Structure-immunosuppressive activity relationships of new analogues of 15-deoxyspergualin. 2. Structural modifications of the spermidine moiety.
AID134271Tested in vivo against mouse graft-versus-host disease(GVHD) for survival (mean) after daily administration of 3 mg/kg (i.p.) using group of 8 mice/dose for 10 days.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Structure-immunosuppressive activity relationships of new analogues of 15-deoxyspergualin. 2. Structural modifications of the spermidine moiety.
AID134267In vivo immunosuppressive activity at a dose of 1 mg/kg in mouse GVHD (graft-versus-host disease) model and the mean survival days evaluated.1999Journal of medicinal chemistry, Jan-28, Volume: 42, Issue:2
Structure-immunosuppressive activity relationships of new analogues of 15-deoxyspergualin. 1. Structural modifications of the hydroxyglycine moiety.
AID1727032Immunosuppressive activity in B6D2F1 mouse model of graft-versus-host disease assessed as mean survival days at 1 mg/kg, ip administered for day 1 to day 10 (day 6 omitted) and measured at day 602020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.
AID1727033Immunosuppressive activity in Lewis rat model of Heart Allotransplantation assessed as mean survival days at 6 mg/kg, ip administered for 10 days by Manntel-Haenszel test2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's10 (47.62)18.2507
2000's9 (42.86)29.6817
2010's1 (4.76)24.3611
2020's1 (4.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (13.64%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (86.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]